← Leaderboards
Konstantinos Alysandratos
Boston University Medical Campus
$1,527,761
Attributed
$1,527,761
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $775.7K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,527,761 · 2
By mechanism
P01$1,041,113 · 1
K08$486,648 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Thomas William Geisbert$89,759,942
- Peter F Weller$19,827,145
- Ronald B Corley$22,442,961
- Max O'Donnell$9,472,250
- Helen E. Jenkins$3,095,244
Others in their field
Other Rising Stars on “Inflammatory”
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Suma Babu · Massachusetts General Hospital$11,004,714
- Sabrina Paganoni · Massachusetts General Hospital$11,004,714
- Christine W Hockett · Avera Mckennan$8,908,366
- Sunni L. Mumford · University Of Pennsylvania$6,439,627
- Robert C Alexander · Banner Health$5,015,602
Research focus
InflammatoryInduced Pluripotent Stem CellFunctional DisorderHuman DiseaseHuman ModelImpairmentFibrosisDisease ModelGenome Wide Association StudyGenesDiagnosisFibrogenesisIdiopathic Interstitial PneumoniaIdiopathic Pulmonary FibrosisAdultCellsCessation Of LifeChildhoodEpitheliumEffective TherapyBiological ModelsGasesAlveolar EpitheliumInterstitial Lung Diseases
Grant awards (5)
Patient-specific iPSCs to model and treat the inception of pulmonary fibrosis$427,602
P01 · FY2025 · HL · contact PI
Utilizing induced pluripotent stem cells to study the role of alveolar type 2 cell dysfunction in pulmonary fibrosis$162,216
K08 · FY2025 · HL · contact PI
Patient-specific iPSCs to model and treat the inception of pulmonary fibrosis$613,511
P01 · FY2024 · HL · contact PI
Utilizing induced pluripotent stem cells to study the role of alveolar type 2 cell dysfunction in pulmonary fibrosis$162,216
K08 · FY2024 · HL · contact PI
Utilizing induced pluripotent stem cells to study the role of alveolar type 2 cell dysfunction in pulmonary fibrosis$162,216
K08 · FY2023 · HL · contact PI